Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Decreases By 22.8%

SOPHiA GENETICS SA (NASDAQ:SOPH) saw a significant decrease in short interest during the month of September. As of September 30th, there was short interest totalling 14,600 shares, a decrease of 22.8% from the September 15th total of 18,900 shares. Based on an average daily trading volume, of 54,500 shares, the short-interest ratio is currently 0.3 days. Approximately 0.0% of the shares of the stock are short sold.

Analysts Set New Price Targets

A number of research firms recently weighed in on SOPH. Royal Bank of Canada reduced their price objective on shares of SOPHiA GENETICS from $8.00 to $7.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Guggenheim assumed coverage on shares of SOPHiA GENETICS in a report on Thursday, June 27th. They set a “buy” rating and a $6.00 target price on the stock. Finally, Morgan Stanley downgraded shares of SOPHiA GENETICS from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $10.00 to $5.00 in a research note on Wednesday, August 7th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Banque Cantonale Vaudoise boosted its holdings in SOPHiA GENETICS by 300.0% during the 2nd quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock valued at $55,000 after acquiring an additional 9,000 shares during the period. Green Alpha Advisors LLC acquired a new stake in shares of SOPHiA GENETICS during the 3rd quarter worth about $79,000. Federated Hermes Inc. increased its stake in SOPHiA GENETICS by 57.5% in the second quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock valued at $289,000 after purchasing an additional 23,000 shares during the last quarter. Moloney Securities Asset Management LLC increased its position in shares of SOPHiA GENETICS by 111.4% during the first quarter. Moloney Securities Asset Management LLC now owns 178,000 shares of the company’s stock worth $878,000 after purchasing an additional 93,800 shares in the last quarter. Finally, Edmond DE Rothschild Holding S.A. increased its holdings in shares of SOPHiA GENETICS by 5.0% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 203,334 shares of the company’s stock valued at $1,002,000 after purchasing an additional 9,700 shares during the period. 31.59% of the stock is currently owned by institutional investors and hedge funds.

SOPHiA GENETICS Price Performance

SOPH stock traded up $0.08 during mid-day trading on Tuesday, reaching $3.46. 9,349 shares of the company’s stock were exchanged, compared to its average volume of 71,575. The company has a market cap of $226.20 million, a price-to-earnings ratio of -3.01 and a beta of 1.03. SOPHiA GENETICS has a 12-month low of $2.70 and a 12-month high of $7.37. The stock’s 50 day moving average is $3.67 and its 200 day moving average is $4.40. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.40 and a quick ratio of 4.17.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Tuesday, August 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.05. The business had revenue of $15.81 million during the quarter, compared to analyst estimates of $17.58 million. SOPHiA GENETICS had a negative net margin of 102.84% and a negative return on equity of 47.40%. During the same quarter in the prior year, the firm earned ($0.33) earnings per share. On average, research analysts expect that SOPHiA GENETICS will post -0.95 EPS for the current year.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.